Original Article

You have full text access to this OnlineOpen article

Evaluation of shark cartilage in patients with advanced cancer†‡

A North Central Cancer Treatment Group trial

  1. Charles L. Loprinzi M.D.1,§,*,
  2. Ralph Levitt M.D.2,
  3. Debra L. Barton R.N., Ph.D.1,
  4. Jeff A. Sloan Ph.D.1,
  5. Pam J. Atherton M.S.1,
  6. Denise J. Smith1,
  7. Shaker R. Dakhil M.D.3,
  8. Dennis F. Moore Jr. M.D.3,
  9. James E. Krook M.D.4,
  10. Kendrith M. Rowland Jr. M.D.5,
  11. Miroslaw A. Mazurczak M.D.6,
  12. Alan R. Berg M.D.7,
  13. George P. Kim M.D.8

Article first published online: 23 MAY 2005

DOI: 10.1002/cncr.21107

Issue

Cancer

Cancer

Volume 104, Issue 1, pages 176–182, 1 July 2005

Additional Information

How to Cite

Loprinzi, C. L., Levitt, R., Barton, D. L., Sloan, J. A., Atherton, P. J., Smith, D. J., Dakhil, S. R., Moore, D. F., Krook, J. E., Rowland, K. M., Mazurczak, M. A., Berg, A. R. and Kim, G. P. (2005), Evaluation of shark cartilage in patients with advanced cancer. Cancer, 104: 176–182. doi: 10.1002/cncr.21107

Author Information

  1. 1

    Departments of Oncology and Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  2. 2

    Meritcare Hospital Community Clinical Oncology Program, Fargo, North Dakota

  3. 3

    Wichita Community Clinical Oncology Program, Wichita, Kansas

  4. 4

    Duluth Community Clinical Oncology Program, Duluth, Minnesota

  5. 5

    Carle Cancer Center Community Clinical Oncology Program, Urbana, Illinois

  6. 6

    Sioux Community Cancer Consortium, Sioux Falls, South Dakota

  7. 7

    Missouri Valley Cancer Consortium Community Clinical Oncology Program, Omaha, Nebraska

  8. 8

    Division of Hematology/Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida

  1. §

    Fax: (507) 284-1803

*Mayo Clinic, 200 First Street SW, Rochester, MN 55905

  1. †

    This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-35113, CA-63849, CA-63848, CA-35195, CA-35272, CA-35269, CA-35103, CA-35101, CA-60276, CA-52352, CA-37417, CA-35448.

  2. ‡

    Additional participating institutions include: CentraCare Clinic, St. Cloud, MN 56301 (Harold E. Windschitl, M.D.); Siouxland Hematology-Oncology Associates, Sioux City, IA 51105 (Donald Wender, M.D.) Iowa Oncology Research Association CCOP, Des Moines, IA 50314 (Roscoe F. Morton, M.D.); Toledo Community Hospital Oncology Program (Paul L. Schaefer, M.D.); Medcenter One Health Systems, Bismarck, ND 58506 (Edward J. Wos, D.O.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld, M.D.); Meritcare Hospital CCOP, Fargo, ND 58122 (Preston Steen, M.D.)

Publication History

  1. Issue published online: 17 JUN 2005
  2. Article first published online: 23 MAY 2005
  3. Manuscript Accepted: 25 FEB 2005
  4. Manuscript Revised: 11 FEB 2005
  5. Manuscript Received: 28 OCT 2004

Funded by

  • Public Health Service. Grant Numbers: CA-25224, CA-37404, CA-35113, CA-63849, CA-63848, CA-35195, CA-35272, CA-35269, CA-35103, CA-35101, CA-60276, CA-52352, CA-37417, CA-35448

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (124K)

REFERENCES

  • 1
    Walker M. Why shark cartilage should succeed against cancer and other pathologies. Medicinal Journalist Report of Innovative Biologics. Townsend Letter for Doctors and Patients. 1991; November: 847–854.
  • 2
    Markman M. Shark cartilage: The laetrile of the 1990s [Editorial]. Clev Clin J Med. 1996; 3: 179–180.
  • 3
    Pettit GR, Ode RH. Antineoplastic agents: Isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark. J Pharm Sci. 1976; 66: 757–758.
    Direct Link:
  • 4
    Gawler I. You can conquer cancer. Melbourne: Hill of Content Publishing, 1984.
  • 5
    Lee A, Langer R. Shark cartilage contains inhibitors of tumor antigenesis. Science. 1983; 221: 1185–1187.
  • 6
    Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
  • 7
    Sugahara K, Ohi Y, Harada T, de Waard P, Vliegenthart JF. Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. I. Six compounds containing 0 or 1 sulfate and/or phosphate residues. J Biol Chem. 1992; 267: 6027–6035.
  • 8
    de Waard P, Vliegenthart JF, Harada T, Sugahara K. Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. II. Seven compounds containing 2 or 3 sulfate residues. J Biol Chem. 1992; 267: 6036–6043.
  • 9
    Moller HJ, Moller-Pedersen T, Damsgaard TE, Poulsen JH. Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage: Implications for ELISA assays. Clin Chim Acta. 1995; 236: 195–204.
  • 10
    Gomes EM, Souto PR, Felzenszwalb I. Shark cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis. Mutat Res. 1996; 367: 204–208.
  • 11
    McKinney EC. Proliferation of shark leukocytes [Letter]. In Vitro Cell Dev Biol. 1992; 28A: 303–305.
  • 12
    Mathews J. Media feeds frenzy over shark cartilage as cancer treatment [News]. J Natl Cancer Inst. 1993; 85: 1190–1191.
  • 13
    Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998; 16: 3649–3655.
  • 14
    Hunt TJ, Connelly JF. Shark cartilage for cancer treatment. Am J Health Syst Pharm. 1995; 52: 1756–1760.
  • 15
    Lowenthal RM. On eye of newt and bone of shark: the dangers of promoting alternative cancer treatments [Editorial; Comment]. Med J Aust. 1994; 160: 323–324.
  • 16
    Blackadar CB. Skeptics of oral administration of shark cartilage [Letter]. Natl Cancer Inst. 1993; 85: 1961–1962.
  • 17
    Pocock SL, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31: 103–115.
  • 18
    Spitzer WO, Dobson AJ, Hall J., et al. Measuring the quality of life of cancer patients. J Chronic Disease. 1981; 34: 585–597.
  • 19
    Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998; 16: 3662–3673.
  • 20
    McCorkle R, Young K.: Development of a symptom distress scale. Cancer Nurs. 1978; 1: 373–378.
  • 21
    Sutherland HJ, Walker P, Till JE. The development of a method for determining oncology patients' emotional distress using linear analogue scales. Cancer Nurs. 1988; 5: 303–308.
  • 22
    Grunberg SM, Groshen S, Steingass S, Zaretsky S, Meyerowitz B. Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res. 1996; 5: 65–72.
  • 23
    Gudex C, Dolan P, Kind P, Williams A. Health state valuations from the general public using the Visual Analogue Scale. Qual Life Res. 1996; 5: 521–531.
  • 24
    Hyland ME, Sodergren SC. Development of a new type of global quality of life scale and comparison and preference for 12 global scales. Qual Life Res. 1996; 5: 469–480.
  • 25
    Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983; 34: 234–239.
  • 26
    Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990; 13: 227–236.
    Direct Link:
  • 27
    Lininger LG, Gail MH, Green SB, Byar DP. Comparison of four tests for equality of survival curves in the presence of stratification and censoring. Biometrika. 1979; 66: 419–428.
  • 28
    Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med. 1997; 16: 1197–1209.
    Direct Link:
  • 29
    Sloan J, Novotny PJ, Loprinzi CL. Analyzing quality-of-life endpoints in clinical trials. SAS Users Group International Proceedings. 1998; 23: 1213–1222.
  • 30
    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 13–22.
  • 31
    Morrison DF. Multivariate statistical methods. New York: McGraw-Hill, 1976.
  • 32
    O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics. 1984; 40: 1079–1087.
  • 33
    Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat-a novel antiangiogenic drug for cancer therapy. Anti-Cancer Drugs. 2003; 14: 91–96.
View Full Article (HTML) Get PDF (124K)